title: Bacterial lipopolysaccharide regulates nociceptin expression in sensory neurons.
abstract: Nociceptin/orphanin FQ (N/OFQ) is an opioid-related peptide that is markedly up-regulated in sensory neurons in vivo following peripheral inflammation and plays a key role in pain physiology. To identify substances that up-regulate N/OFQ expression in sensory neurons, we carried out an in vitro screen using purified adult mouse dorsal root ganglion (DRG) neurons and identified the potent proinflammatory agent bacterial lipopolysaccharide (LPS) as a very effective inducer of N/OFQ. The robust response of these neurons to LPS enabled us to identify the components of a putative neuronal LPS receptor complex. In contrast to the immune system, where the functional LPS receptor complex is composed of CD-14 together with either MD-2 and TLR4 on myeloid cells or the homologous receptors MD-1 and RP105 on mature B cells, DRG neurons express the unusual combination of CD-14, TLR4, and MD-1. Blocking antibodies against TLR4 and MD-1 prevented induction of N/OFQ by LPS, and, in immunoprecipitation experiments, MD-1 coprecipitated with TLR4. Our findings suggest that LPS regulates N/OFN expression in sensory neurons via a novel combination of LPS receptor components and demonstrate for the first time a direct action of a key initiator of innate immune responses on neurons.
authors.affiliation: School of Biosciences, Cardiff, United Kingdom.
authors.forename: Cristian
authors.initials: C
authors.lastname: Acosta
authors.forename: Alun
authors.initials: A
authors.lastname: Davies
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D000954:Antigens, Surface / Q000187:drug effects / Q000378:metabolism; D002460:Cell Line; D002478:Cells, Cultured; D005727:Ganglia, Spinal / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects / Q000276:immunology; D007249:Inflammation / Q000139:chemically induced / Q000276:immunology / Q000378:metabolism; D018836:Inflammation Mediators / Q000494:pharmacology; D018950:Lipopolysaccharide Receptors / Q000187:drug effects / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008562:Membrane Glycoproteins / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D009475:Neurons, Afferent / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D018847:Opioid Peptides / Q000187:drug effects / Q000378:metabolism*; D010146:Pain / Q000139:chemically induced / Q000276:immunology / Q000378:metabolism*; D051197:Toll-Like Receptor 4 / Q000187:drug effects / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects / Q000276:immunology; D000097629:Nociceptin
chemical_list: D000906:Antibodies; D000954:Antigens, Surface; D018836:Inflammation Mediators; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; D018847:Opioid Peptides; D051197:Toll-Like Receptor 4; D000097629:Nociceptin; C113553:Ly86 protein, mouse; C493487:Tlr4 protein, mouse